Georgia lawmakers are hoping to pass a bill before the legislative session ends Friday that would allow pharmacists to distribute HIV prevention medicines without a prescription, a policy change that ...
14h
Zacks Investment Research on MSNGilead Sciences (GILD) Ascends While Market Falls: Some Facts to NoteIn the latest market close, Gilead Sciences (GILD) reached $112.39, with a +0.45% movement compared to the previous day. The stock outperformed the S&P 500, which registered a daily loss of 4.84%. On ...
Gilead’s HIV franchise generated $19.612B in 2024, but faces future funding challenges. Learn why GILD stock is a "Hold" amid ...
Tomas Cihlar knew all too well that despite initial successes with combination treatment, HIV was firmly holding ground ...
Key to 400-employee Denali's submission is the FDA allowing measurement of a type of GAG, called heparan sulfate, in ...
1d
Zacks Investment Research on MSNGilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should KnowGilead Sciences (GILD) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some ...
Three other Bay Area companies — Mirum Therapeutics Inc. (Nasdaq: MIRM), Soleno Therapeutics Inc. (Nasdaq: SLNO) and Exelixis ...
On the same day the Trump Administration unceremoniously shut down the U.S. Department of Health and Human Services Regional ...
PEPFAR had been set to lead the rollout of Gilead Science's lenacapavir, which has been hailed as a "miracle" of HIV ...
As of the end of 2023, nearly 40 million people worldwide were living with HIV, including approximately 1.2 million in the ...
Vaccine makers were hit particularly hard yesterday, as Marks’ resignation letter alluded to disagreements with HHS Secretary ...
Gilead CEO Daniel O’Day saw another rise in his pay in 2024, reflecting the steadily upward trajectory of the company since ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results